// App-Quantinova.ai

1430 : Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis

Researchers

Presenter

  • Sasha Bernatsky

Principal Investigators

  • Cristiano Moura

  • Luck Lukusa

  • Laura Yan

  • Walter P Maksymowych

  • Denis Choquette

  • Gilles Boire

Medical Centers

  • Research Institute McGill University Health Center, Montreal, Quebec, Canada

  • Department of Surgery, University of Alberta, Edmonton, AB, Canada

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Universite de Sherbrooke, Sherbrooke, QC, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • C reactive protein

  • Estrogen receptor alpha

  • TNF Receptor Superfamily Member 1B

  • Body mass index

Drug/Treatment

  • Etanercept biosimilar

  • Hydroxychloroquine

  • Methotrexate

  • Etanercept

  • CHS-0214

Outcome

  • N/A

Study Design

  • Prospective

  • Cohort

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved